Nathan Hubbard

Nathan Hubbard is the Vice President of Oncology and Diagnostics Business Development Transactions, for Eli Lilly and Company. He joined Lilly 14 years ago and has had a broad set of roles, including 6 years of oncology-specific experience. From 2012-2014, he ran the oncology business unit for Eli Lilly Canada. Previously, he had oncology sales and marketing leadership positions in China and San Francisco. Prior to this he was a Director of Mergers and Acquisitions in Eli Lilly’s Corporate Finance and Investment Banking (CFIB) Group, where he was responsible for executing the company’s oncology M&A strategy. Upon returning from business school, he was a Consultant in Lilly Finance’s Six Sigma organization. While completing his MBA, Nathan interned at Genentech where he worked on Herceptin marketing.